The British drugmaker GSK has struck an agreement to make a payment of up to $2.2bn (£1.7bn) to resolve litigation brought in the US over its heartburn treatment Zantac.
The company said it had struck agreements with 10 plaintiff law firms who represent about 93%, roughly 80,000, of the US state court product liability cases pending against it.
The company said in a stock market statement on Wednesday that it would make the aggregate payment to resolve all such cases handled by those plaintiff firms that meet agreed eligibility and participation criteria.
The claimants had alleged their cancers were linked to Zantac, known generically as ranitidine. GSK had argued there was no evidence to suggest an increased cancer risk and has not admitted any liability in the settlements.
The world’s largest hornet, an invasive breed nicknamed the “murder hornet” for its dangerous sting and...
More than two months after Missouri residents voted to add abortion rights into their state constitution...
